• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

Is the Change in Gestational Age Distribution in the US Having an Effect on Perinatal Mortality?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Ananth et al. (JAMA Pediatrics, 2018) examined the shifting US gestational age distributions in an effort to determine if there has been any effect on perinatal mortality rates.

METHODS:

  • Retrospective cohort study
    • Live birth and infant death data were linked (2007 – 2015)
    • >35 million singleton births
  • The study compared the year of birth and changes in gestational age distribution

Outcomes

  • Change in proportion of births at 8 gestational age ranges
    • 20 to 27 | 28 to 31 | 32 to 33 | 34 to 36 | 37 to 38 | 39 to 40 | 41 | 42 to 44 weeks
  • Changes in perinatal mortality rates
    • Stillbirths at ≥20 weeks
    • Neonatal deaths at <28 days
  • Contribution of gestational age distribution changes to perinatal mortality

RESULTS:

  • 34,236,577 live births during the study period
  • Proportion of births at all gestational ages declined, except at 39 to 40 weeks
    • increased by 54.5% in 2007 and 60.2% 2015
  • Perinatal mortality overall declined (9.0 to 8.6 per 1000 births)
    • Stillbirths declined (5.7 to 5.6 per 1000 births)
    • Neonatal mortality declined (3.3 to 3.0 per 1000 births)
  • Adjusted annual relative increase in perinatal mortality rates were seen in the following gestational age groups
    • 34 to 36 wks: 1.0% (95% CI, 0.6%-1.4%)
    • 37 to 38 wks: 2.3% (95% CI, 1.9%-2.8%)
    • 42 to 44 wks: 4.2% (95% CI, 1.5%-7.0%)
  • Adjusted annual relative decline in perinatal mortality was seen in the following gestational age group
    • 39 and 40 wks: −1.3% (95% CI, −1.8% to −0.9%)
  • Adjusted annual relative increase in neonatal mortality rates were seen in the following gestational age groups
    • 34 to 36 wks: 0.9% (95% CI, 0.2%-1.6%)
    • 37 to 38 wks: 3.1% (95% CI, 2.1%-4.1%)
  • Decline in neonatal mortality rate was related to change in gestational age distribution and not age–specific mortality

CONCLUSION:

  • Decreasing proportion of births at 34-36 weeks and 37-38 weeks may be due to new policies regarding limiting elective deliveries to ≥39 weeks
  • Proportion of births at gestational age 39-40 weeks increased, while perinatal mortality at 39-40 weeks declined
  • This finding may be the result of pregnancies delivered at 39 to 40 weeks that previously would have been unnecessarily delivered earlier, leaving fetuses at higher risk for mortality at other gestational ages
  • However, the authors note that this study is not designed to determine the cause of why perinatal and neonatal mortality rates increased in the 34-36 and 37-38 week groups and state

“A possible reason for the increased mortality at a gestational age of 37 to 38 weeks could be that physicians may be more likely to defer to 39 weeks for delivery for women at moderately increased risk for adverse perinatal outcomes. With fewer obstetric interventions for early-term pregnancies, the risk may have increased for women approaching 39 weeks’ gestation.”

Learn More – Primary Sources:

Association of Temporal Changes in Gestational Age With Perinatal Mortality in the United States, 2007-2015

image_pdfFavoriteLoadingFavorite

< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

What is the Best Course of Action Following PPROM Between 24 and 37 Weeks?
Do Twins or Singletons Have a Higher Rate of Preterm Mortality?
Forceps/Vacuum Delivery vs Cesarean Section and Adverse Maternal and Perinatal Outcomes

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Download Your ObG App
HERE!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site